Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.
about
The 15th Bangkok International Symposium on HIV MedicineGetting to 90-90-90 in paediatric HIV: What is needed?Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts.Impairment of the activin A autocrine loop by lopinavir reduces self-renewal of distinct human adipose progenitors.Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyMetabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenHigh Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral TherapyEffect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Metabolic complications and treatment of perinatally HIV-infected children and adolescents.Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.Paediatric HIV grows up: recent advances in perinatally acquired HIV.Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.Anthropometry and body composition of vertically HIV-infected children and adolescents under therapy with and without protease inhibitors.Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.Accuracy of octa-polar bioelectrical impedance analysis for the assessment of total and appendicular body composition in children and adolescents with HIV: comparison with dual energy X-ray absorptiometry and air displacement plethysmography.Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study
P2860
Q29396779-2F023D18-CA69-4B27-921D-6838978601B0Q30385352-C0A57EF7-B7D3-4E92-8BB0-B4DCAB035B32Q30978868-C39DBDB0-2537-4A90-805C-EAE0EA69D4C1Q33774103-A8A01ABC-BA6C-43FA-830A-1D1401E8DB36Q35205900-8FBD6087-66C4-4AE9-BE45-F80C42425A98Q35945312-F1D1E0D6-E4F0-42BC-9FA2-820CC7B1DD6EQ36349683-C5DA77D2-6387-42C8-85F7-0162BD885344Q36449095-51D2A079-1EB2-4EBC-8457-2246B501E1E1Q36558893-9A545B38-E602-404C-B1A3-BFBA887680EFQ36646867-1119635E-8313-40AE-B603-8EBBAA97D27AQ36952291-AF50320A-3713-46C8-B1DB-C53F5984A329Q37724319-BDE4714C-EDE3-40DE-81A9-F371F52C6D58Q38108736-A0994E8E-DF2B-4825-B87E-B121960E4903Q38130905-C024481F-8620-42E6-898F-B8013EC3DA3BQ38245999-B8E4479A-70CD-4FC3-8FEC-A2E0EA81B774Q41505058-676DAA4B-29D9-4E99-853F-94833F39CDFEQ42200499-B73F300C-1E3F-424F-ABBF-636F0C5C8F88Q44677110-6498C5B1-204B-4F68-BBD1-8FBF1A5C3BEEQ48056206-805F0725-4A09-45D9-9838-D05E8F17F1B7Q53695978-0386C3B7-5AA7-4BE3-84E3-31E3AF7577F4Q58798902-875F9192-399F-4FAC-B83D-2DEA644B4E6A
P2860
Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Body fat abnormality in HIV-in ...... : prevalence and risk factors.
@ast
Body fat abnormality in HIV-in ...... : prevalence and risk factors.
@en
type
label
Body fat abnormality in HIV-in ...... : prevalence and risk factors.
@ast
Body fat abnormality in HIV-in ...... : prevalence and risk factors.
@en
prefLabel
Body fat abnormality in HIV-in ...... : prevalence and risk factors.
@ast
Body fat abnormality in HIV-in ...... : prevalence and risk factors.
@en
P2093
P2860
P1476
Body fat abnormality in HIV-in ...... : prevalence and risk factors.
@en
P2093
Alessandra Vigano
European Paediatric HIV and Lipodystrophy Study Group in EuroCoord
Mario Cortina-Borja
Naufil Alam
Tessa Goetghebuer
P2860
P304
P356
10.1097/QAI.0B013E31824330CB
P407
P577
2012-03-01T00:00:00Z